{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T06:55:09Z","timestamp":1771484109815,"version":"3.50.1"},"reference-count":89,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2024,5,6]],"date-time":"2024-05-06T00:00:00Z","timestamp":1714953600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,5,6]],"date-time":"2024-05-06T00:00:00Z","timestamp":1714953600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Rheumatol Rep"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1007\/s11926-024-01150-z","type":"journal-article","created":{"date-parts":[[2024,5,6]],"date-time":"2024-05-06T07:02:49Z","timestamp":1714978969000},"page":"290-301","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Kidney Failure in Pauci-immune Crescentic Glomerulonephritis: Rationale for Immunosuppression to Improve Kidney Outcome"],"prefix":"10.1007","volume":"26","author":[{"given":"Faten","family":"Aqeel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Duvuru","family":"Geetha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,5,6]]},"reference":[{"issue":"5","key":"1150_CR1","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1007\/s10157-013-0869-6","volume":"17","author":"JC Jennette","year":"2013","unstructured":"Jennette JC. Overview of the 2012 revised International Chapel Hill Consensus Conference nomenclature of vasculitides. Clin Exp Nephrol. 2013;17(5):603\u20136. https:\/\/doi.org\/10.1007\/s10157-013-0869-6.","journal-title":"Clin Exp Nephrol"},{"issue":"1","key":"1150_CR2","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1053\/j.ajkd.2019.04.031","volume":"75","author":"D Geetha","year":"2020","unstructured":"Geetha D, Jefferson JA. ANCA-Associated vasculitis: core curriculum 2020. Am J Kidney Dis. 2020;75(1):124\u201337. https:\/\/doi.org\/10.1053\/j.ajkd.2019.04.031.","journal-title":"Am J Kidney Dis"},{"issue":"3","key":"1150_CR3","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1097\/MNH.0000000000000596","volume":"29","author":"L Anguiano","year":"2020","unstructured":"Anguiano L, Kain R, Anders HJ. The glomerular crescent: triggers, evolution, resolution, and implications for therapy. Curr Opin Nephrol Hypertens. 2020;29(3):302\u20139. https:\/\/doi.org\/10.1097\/MNH.0000000000000596.","journal-title":"Curr Opin Nephrol Hypertens"},{"issue":"4","key":"1150_CR4","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1016\/j.kint.2017.11.023","volume":"93","author":"IM Bajema","year":"2018","unstructured":"Bajema IM, Wilhelmus S, Alpers CE, et al. Revision of the international society of nephrology\/renal pathology society classification for lupus nephritis: clarification of definitions, and modified National Institutes of Health activity and chronicity indices. Kidney Int. 2018;93(4):789\u201396. https:\/\/doi.org\/10.1016\/j.kint.2017.11.023.","journal-title":"Kidney Int"},{"issue":"4","key":"1150_CR5","doi-asserted-by":"publisher","first-page":"102495","DOI":"10.1016\/j.autrev.2020.102495","volume":"19","author":"A Kronbichler","year":"2020","unstructured":"Kronbichler A, Shin JI, Lee KH, et al. Clinical associations of renal involvement in ANCA-associated vasculitis. Autoimmun Rev. 2020;19(4):102495. https:\/\/doi.org\/10.1016\/j.autrev.2020.102495.","journal-title":"Autoimmun Rev"},{"key":"1150_CR6","doi-asserted-by":"publisher","unstructured":"Alamo BS, Moi L, Bajema I, et al. Long-term outcome of kidney function in patients with ANCA-associated vasculitis. Nephrol Dial Transplant. Published online January 24, 2024. https:\/\/doi.org\/10.1093\/ndt\/gfae018.","DOI":"10.1093\/ndt\/gfae018"},{"issue":"9","key":"1150_CR7","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.1136\/annrheumdis-2016-210942","volume":"76","author":"JA Tan","year":"2017","unstructured":"Tan JA, Dehghan N, Chen W, Xie H, Esdaile JM, Avina-Zubieta JA. Mortality in ANCA-associated vasculitis: ameta-analysis of observational studies. Ann Rheum Dis. 2017;76(9):1566\u201374. https:\/\/doi.org\/10.1136\/annrheumdis-2016-210942.","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"1150_CR8","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1002\/art.39614","volume":"68","author":"RL Rhee","year":"2016","unstructured":"Rhee RL, Hogan SL, Poulton CJ, et al. Trends in long-term outcomes among patients with antineutrophil cytoplasmic antibody-associated vasculitis with renal disease. Arthritis Rheumatol. 2016;68(7):1711\u201320. https:\/\/doi.org\/10.1002\/art.39614.","journal-title":"Arthritis Rheumatol"},{"key":"1150_CR9","doi-asserted-by":"publisher","first-page":"152189","DOI":"10.1016\/j.semarthrit.2023.152189","volume":"60","author":"V Pope","year":"2023","unstructured":"Pope V, Sivashanmugathas V, Moodley D, Gunaratnam L, Barra L. Outcomes in ANCA-associated vasculitis patients with end-stage kidney disease on renal replacement therapy-a meta-analysis. Semin Arthritis Rheum. 2023;60:152189. https:\/\/doi.org\/10.1016\/j.semarthrit.2023.152189.","journal-title":"Semin Arthritis Rheum"},{"key":"1150_CR10","doi-asserted-by":"publisher","unstructured":"Li W, Huang H, Cai M, Yuan T, Sheng Y. Antineutrophil Cytoplasmic Antibody-Associated Vasculitis Update: Genetic Pathogenesis. Front Immunol. 2021;12:624848. Published 2021 Mar 26. https:\/\/doi.org\/10.3389\/fimmu.2021.624848.","DOI":"10.3389\/fimmu.2021.624848"},{"issue":"5","key":"1150_CR11","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1002\/art.40034","volume":"69","author":"PA Merkel","year":"2017","unstructured":"Merkel PA, Xie G, Monach PA, et al. Identification of functional and expression polymorphisms associated with risk for antineutrophil cytoplasmic autoantibody-associated vasculitis. Arthritis Rheumatol. 2017;69(5):1054\u201366. https:\/\/doi.org\/10.1002\/art.40034.","journal-title":"Arthritis Rheumatol"},{"issue":"11","key":"1150_CR12","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1002\/art.41767","volume":"73","author":"S Giorgiutti","year":"2021","unstructured":"Giorgiutti S, Dieudonne Y, Hinschberger O, et al. Prevalence of antineutrophil cytoplasmic antibody-associated vasculitis and spatial association with quarries in a Region of Northeastern France: a capture-recapture and geospatial analysis. Arthritis Rheumatol. 2021;73(11):2078\u201385. https:\/\/doi.org\/10.1002\/art.41767.","journal-title":"Arthritis Rheumatol"},{"issue":"5663","key":"1150_CR13","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1126\/science.1092385","volume":"303","author":"V Brinkmann","year":"2004","unstructured":"Brinkmann V, Reichard U, Goosmann C, et al. Neutrophil extracellular traps kill bacteria. Science. 2004;303(5663):1532\u20135. https:\/\/doi.org\/10.1126\/science.1092385.","journal-title":"Science"},{"key":"1150_CR14","doi-asserted-by":"publisher","unstructured":"S\u00f6derberg D, Segelmark M. Neutrophil extracellular traps in ANCA-associated vasculitis. Front Immunol. 2016;7:256. Published 2016 Jun 30. https:\/\/doi.org\/10.3389\/fimmu.2016.00256.","DOI":"10.3389\/fimmu.2016.00256"},{"key":"1150_CR15","doi-asserted-by":"publisher","unstructured":"Tsukui D, Kimura Y, Kono H. Pathogenesis and pathology of anti-neutrophil cytoplasmic antibody(ANCA) -associated vasculitis. J Transl Autoimmun. 2021;4:100094. Published 2021 Mar 3. https:\/\/doi.org\/10.1016\/j.jtauto.2021.100094.","DOI":"10.1016\/j.jtauto.2021.100094"},{"issue":"3","key":"1150_CR16","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1016\/j.kint.2017.09.018","volume":"93","author":"J Dick","year":"2018","unstructured":"Dick J, Gan PY, Ford SL, et al. C5a receptor 1 promotes autoimmunity, neutrophil dysfunction and injury in experimental anti-myeloperoxidase glomerulonephritis. Kidney Int. 2018;93(3):615\u201325. https:\/\/doi.org\/10.1016\/j.kint.2017.09.018.","journal-title":"Kidney Int"},{"issue":"1","key":"1150_CR17","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1038\/ki.2012.313","volume":"83","author":"SJ Gou","year":"2013","unstructured":"Gou SJ, Yuan J, Chen M, Yu F, Zhao MH. Circulating complement activation in patients with anti-neutrophil cytoplasmic antibody-associated vasculitis. Kidney Int. 2013;83(1):129\u201337. https:\/\/doi.org\/10.1038\/ki.2012.313.","journal-title":"Kidney Int"},{"key":"1150_CR18","doi-asserted-by":"publisher","unstructured":"\u2022\u2022 Jayne DRW, Merkel PA, Schall TJ, Bekker P; ADVOCATE Study Group. Avacopan for the Treatment of ANCA-Associated Vasculitis [published correction appears in N Engl J Med. 2024 Jan 25;390(4):388]. N Engl J Med. 2021;384(7):599\u2013609. https:\/\/doi.org\/10.1056\/NEJMoa2023386. This is a phase 3 clinical trial which showed efficacy of avacopan for remission induction leading to FDA approval.","DOI":"10.1056\/NEJMoa2023386"},{"issue":"11","key":"1150_CR19","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1007\/s00296-017-3818-y","volume":"37","author":"L Shi","year":"2017","unstructured":"Shi L. Anti-neutrophil cytoplasmic antibody-associated vasculitis: prevalence, treatment, and outcomes. Rheumatol Int. 2017;37(11):1779\u201388. https:\/\/doi.org\/10.1007\/s00296-017-3818-y.","journal-title":"Rheumatol Int"},{"issue":"5","key":"1150_CR20","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1002\/art.40776","volume":"71","author":"S Gopaluni","year":"2019","unstructured":"Gopaluni S, Flossmann O, Little MA, et al. Effect of disease activity at three and six months after diagnosis on long-term outcomes in antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheumatol. 2019;71(5):784\u201391. https:\/\/doi.org\/10.1002\/art.40776.","journal-title":"Arthritis Rheumatol"},{"issue":"6","key":"1150_CR21","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1159\/000494840","volume":"48","author":"S Menez","year":"2018","unstructured":"Menez S, Hruskova Z, Scott J, et al. Predictors of renal outcomes in sclerotic class anti-neutrophil cytoplasmic antibody glomerulonephritis. Am J Nephrol. 2018;48(6):465\u201371. https:\/\/doi.org\/10.1159\/000494840.","journal-title":"Am J Nephrol"},{"key":"1150_CR22","doi-asserted-by":"publisher","unstructured":"Novick TK, Chen M, Scott J, et al. Patient outcomes in renal-limited antineutrophil cytoplasmic antibody vasculitis with inactive histology. Kidney Int Rep. 2018;3(3):671\u2013676. Published 2018 Feb 21. https:\/\/doi.org\/10.1016\/j.ekir.2018.01.012.","DOI":"10.1016\/j.ekir.2018.01.012"},{"key":"1150_CR23","doi-asserted-by":"publisher","unstructured":"de Lind van Wijngaarden RA, Hauer HA, Wolterbeek R, et al. Chances of renal recovery for dialysis-dependent ANCA-associated glomerulonephritis [published correction appears in J Am Soc Nephrol. 2007 Dec;18(12):3206. Pusey, Charles D [added]]. J Am Soc Nephrol. 2007;18(7):2189\u20132197. https:\/\/doi.org\/10.1681\/ASN.2007010066.","DOI":"10.1681\/ASN.2007010066"},{"issue":"5","key":"1150_CR24","doi-asserted-by":"publisher","first-page":"905","DOI":"10.2215\/CJN.08290813","volume":"9","author":"T Lee","year":"2014","unstructured":"Lee T, Gasim A, Derebail VK, et al. Predictors of treatment outcomes in ANCA-associated vasculitis with severe kidney failure. Clin J Am Soc Nephrol. 2014;9(5):905\u201313. https:\/\/doi.org\/10.2215\/CJN.08290813.","journal-title":"Clin J Am Soc Nephrol"},{"key":"1150_CR25","doi-asserted-by":"publisher","unstructured":"\u2022\u2022 Kidney Disease: Improving Global Outcomes (KDIGO) ANCA Vasculitis Work Group. KDIGO 2024 Clinical practice guideline for the management of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis. Kidney Int. 2024;105(3S):S71-S116. https:\/\/doi.org\/10.1016\/j.kint.2023.10.008. This paper provides guidelines for remission induction and maintenance therapy for AAV based on evidence to date.","DOI":"10.1016\/j.kint.2023.10.008"},{"key":"1150_CR26","doi-asserted-by":"publisher","unstructured":"Hellmich B, Sanchez-Alamo B, Schirmer JH, et al. EULAR recommendations for the management of ANCA-associated vasculitis: 2022 update. Ann Rheum Dis. 2024;83(1):30\u201347. Published 2024 Jan 2. https:\/\/doi.org\/10.1136\/ard-2022-223764.","DOI":"10.1136\/ard-2022-223764"},{"issue":"6","key":"1150_CR27","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1016\/j.kint.2018.07.020","volume":"94","author":"SR Brix","year":"2018","unstructured":"Brix SR, Noriega M, Tennstedt P, et al. Development and validation of a renal risk score in ANCA-associated glomerulonephritis. Kidney Int. 2018;94(6):1177\u201388. https:\/\/doi.org\/10.1016\/j.kint.2018.07.020.","journal-title":"Kidney Int"},{"issue":"3","key":"1150_CR28","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1681\/ASN.0000000000000274","volume":"35","author":"S Bate","year":"2024","unstructured":"Bate S, McGovern D, Costigliolo F, et al. The improved kidney risk score in ANCA-associated vasculitis for clinical practice and trials. J Am Soc Nephrol. 2024;35(3):335\u201346. https:\/\/doi.org\/10.1681\/ASN.0000000000000274.","journal-title":"J Am Soc Nephrol"},{"issue":"10","key":"1150_CR29","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1681\/ASN.2010050477","volume":"21","author":"AE Berden","year":"2010","unstructured":"Berden AE, Ferrario F, Hagen EC, et al. Histopathologic classification of ANCA-associated glomerulonephritis. J Am Soc Nephrol. 2010;21(10):1628\u201336. https:\/\/doi.org\/10.1681\/ASN.2010050477.","journal-title":"J Am Soc Nephrol"},{"issue":"9","key":"1150_CR30","doi-asserted-by":"publisher","first-page":"1710","DOI":"10.1093\/ndt\/gfab250","volume":"37","author":"M Casal Moura","year":"2022","unstructured":"Casal Moura M, Fervenza FC, Specks U, Sethi S. Kidney biopsy chronicity grading in antineutrophil cytoplasmic antibody-associated vasculitis. Nephrol Dial Transplant. 2022;37(9):1710\u201321. https:\/\/doi.org\/10.1093\/ndt\/gfab250.","journal-title":"Nephrol Dial Transplant"},{"issue":"10","key":"1150_CR31","doi-asserted-by":"publisher","first-page":"670","DOI":"10.7326\/0003-4819-150-10-200905190-00004","volume":"150","author":"K de Groot","year":"2009","unstructured":"de Groot K, Harper L, Jayne DR, et al. Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial. Ann Intern Med. 2009;150(10):670\u201380. https:\/\/doi.org\/10.7326\/0003-4819-150-10-200905190-00004.","journal-title":"Ann Intern Med"},{"issue":"6","key":"1150_CR32","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1136\/annrheumdis-2011-200477","volume":"71","author":"L Harper","year":"2012","unstructured":"Harper L, Morgan MD, Walsh M, et al. Pulse versus daily oral cyclophosphamide for induction of remission in ANCA-associated vasculitis: long-term follow-up. Ann Rheum Dis. 2012;71(6):955\u201360. https:\/\/doi.org\/10.1136\/annrheumdis-2011-200477.","journal-title":"Ann Rheum Dis"},{"key":"1150_CR33","unstructured":"Ogino MH, Tadi P. Cyclophosphamide. In: StatPearls. Treasure Island (FL): StatPearls Publishing; July 3, 2023."},{"key":"1150_CR34","doi-asserted-by":"publisher","unstructured":"Chanouzas D, McGregor JAG, Nightingale P, et al. Intravenous pulse methylprednisolone for induction of remission in severe ANCA associated vasculitis: a multi-center retrospective cohort study. BMC Nephrol. 2019;20(1):58. Published 2019 Feb 18. https:\/\/doi.org\/10.1186\/s12882-019-1226-0.","DOI":"10.1186\/s12882-019-1226-0"},{"key":"1150_CR35","doi-asserted-by":"publisher","unstructured":"Neumann I. Immunosuppressive and glucocorticoid therapy for the treatment of ANCA-asssociated vasculitis. Rheumatology (Oxford). 2020;59(Suppl 3):iii60-iii67. https:\/\/doi.org\/10.1093\/rheumatology\/keaa035.","DOI":"10.1093\/rheumatology\/keaa035"},{"issue":"7","key":"1150_CR36","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1056\/NEJMoa1803537","volume":"382","author":"M Walsh","year":"2020","unstructured":"\u2022\u2022 Walsh M, Merkel PA, Peh CA, et al. Plasma exchange and glucocorticoids in severe ANCA-associated vasculitis. N Engl J Med. 2020;382(7):622\u201331. https:\/\/doi.org\/10.1056\/NEJMoa1803537. (This trial tested the efficacy of plasma exchange and two different glucocorticoid dosing regimens for remission indcution in AAV.)","journal-title":"N Engl J Med"},{"key":"1150_CR37","doi-asserted-by":"publisher","unstructured":"Junek ML, Merkel PA, Vilayur E, et al. The risk of relapse of ANCA-associated vasculitis in a randomized controlled trial of plasma exchange and glucocorticoids. Arthritis Rheumatol. Published online March 14, 2024. https:\/\/doi.org\/10.1002\/art.42843.","DOI":"10.1002\/art.42843"},{"issue":"21","key":"1150_CR38","doi-asserted-by":"publisher","first-page":"2178","DOI":"10.1001\/jama.2021.6615","volume":"325","author":"S Furuta","year":"2021","unstructured":"Furuta S, Nakagomi D, Kobayashi Y, et al. Effect of reduced-dose vs high-dose glucocorticoids added to rituximab on remission induction in ANCA-associated vasculitis: a randomized clinical trial. JAMA. 2021;325(21):2178\u201387. https:\/\/doi.org\/10.1001\/jama.2021.6615.","journal-title":"JAMA"},{"key":"1150_CR39","doi-asserted-by":"publisher","unstructured":"Xiao Y, Guyatt G, Zeng L, et al. Comparative efficacy and safety of alternative glucocorticoids regimens in patients with ANCA-associated vasculitis: a systematic review. BMJ Open. 2022;12(2):e050507. Published 2022 Feb 25. https:\/\/doi.org\/10.1136\/bmjopen-2021-050507.","DOI":"10.1136\/bmjopen-2021-050507"},{"key":"1150_CR40","doi-asserted-by":"publisher","unstructured":"Zeng L, Walsh M, Guyatt GH, et al. Plasma exchange and glucocorticoid dosing for patients with ANCA-associated vasculitis: a clinical practice guideline. BMJ. 2022;376:e064597. Published 2022 Feb 25. https:\/\/doi.org\/10.1136\/bmj-2021-064597.","DOI":"10.1136\/bmj-2021-064597"},{"issue":"3","key":"1150_CR41","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1056\/NEJMoa0909905","volume":"363","author":"JH Stone","year":"2010","unstructured":"Stone JH, Merkel PA, Spiera R, et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med. 2010;363(3):221\u201332. https:\/\/doi.org\/10.1056\/NEJMoa0909905.","journal-title":"N Engl J Med"},{"issue":"3","key":"1150_CR42","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1056\/NEJMoa0909169","volume":"363","author":"RB Jones","year":"2010","unstructured":"Jones RB, Tervaert JW, Hauser T, et al. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med. 2010;363(3):211\u201320. https:\/\/doi.org\/10.1056\/NEJMoa0909169.","journal-title":"N Engl J Med"},{"issue":"4","key":"1150_CR43","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1681\/ASN.2014010046","volume":"26","author":"D Geetha","year":"2015","unstructured":"Geetha D, Specks U, Stone JH, et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis with renal involvement. J Am Soc Nephrol. 2015;26(4):976\u201385. https:\/\/doi.org\/10.1681\/ASN.2014010046.","journal-title":"J Am Soc Nephrol"},{"issue":"4","key":"1150_CR44","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1038\/nrneph.2016.20","volume":"12","author":"F Hiepe","year":"2016","unstructured":"Hiepe F, Radbruch A. Plasma cells as an innovative target in autoimmune disease with renal manifestations. Nat Rev Nephrol. 2016;12(4):232\u201340. https:\/\/doi.org\/10.1038\/nrneph.2016.20.","journal-title":"Nat Rev Nephrol"},{"key":"1150_CR45","doi-asserted-by":"publisher","unstructured":"McAdoo SP, Medjeral-Thomas N, Gopaluni S, et al. Long-term follow-up of a combined rituximab and cyclophosphamide regimen in renal anti-neutrophil cytoplasm antibody-associated vasculitis [published correction appears in Nephrol Dial Transplant. 2018 May 1;33(5):899]. Nephrol Dial Transplant. 2019;34(1):63\u201373. https:\/\/doi.org\/10.1093\/ndt\/gfx378.","DOI":"10.1093\/ndt\/gfx378"},{"issue":"6","key":"1150_CR46","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1016\/j.kint.2021.08.025","volume":"100","author":"K Gulati","year":"2021","unstructured":"\u2022\u2022 Gulati K, Edwards H, Prendecki M, et al. Combination treatment with rituximab, low-dose cyclophosphamide and plasma exchange for severe antineutrophil cytoplasmic antibody-associated vasculitis. Kidney Int. 2021;100(6):1316\u201324. https:\/\/doi.org\/10.1016\/j.kint.2021.08.025. (Observational study showing the efficacy and safety of combination of cyclophosphamide and rituximab with glucocorticoids for remission induction in AAV.)","journal-title":"Kidney Int"},{"key":"1150_CR47","doi-asserted-by":"publisher","unstructured":"Cortazar FB, Muhsin SA, Pendergraft WF 3rd, et al. Combination therapy with rituximab and cyclophosphamide for remission induction in ANCA vasculitis. Kidney Int Rep. 2017;3(2):394\u2013402. Published 2017 Nov 14. https:\/\/doi.org\/10.1016\/j.ekir.2017.11.004.","DOI":"10.1016\/j.ekir.2017.11.004"},{"key":"1150_CR48","doi-asserted-by":"publisher","unstructured":"van Leeuwen JR, Bredewold OW, van Dam LS, et al. Compassionate use of avacopan in difficult-to-treat antineutrophil cytoplasmic antibody-associated vasculitis. Kidney Int Rep. 2021;7(3):624\u2013628. Published 2021 Dec 8. https:\/\/doi.org\/10.1016\/j.ekir.2021.11.036.","DOI":"10.1016\/j.ekir.2021.11.036"},{"issue":"7","key":"1150_CR49","doi-asserted-by":"publisher","first-page":"2180","DOI":"10.1681\/ASN.2007010090","volume":"18","author":"DR Jayne","year":"2007","unstructured":"Jayne DR, Gaskin G, Rasmussen N, et al. Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis. J Am Soc Nephrol. 2007;18(7):2180\u20138. https:\/\/doi.org\/10.1681\/ASN.2007010090.","journal-title":"J Am Soc Nephrol"},{"key":"1150_CR50","doi-asserted-by":"publisher","unstructured":"Walsh M, Collister D, Zeng L, et al. The effects of plasma exchange in patients with ANCA-associated vasculitis: an updated systematic review and meta-analysis. BMJ. 2022;376:e064604. Published 2022 Feb 25. https:\/\/doi.org\/10.1136\/bmj-2021-064604.","DOI":"10.1136\/bmj-2021-064604"},{"key":"1150_CR51","doi-asserted-by":"publisher","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group. KDIGO 2021 clinical practice guideline for the management of glomerular diseases. Kidney Int. 2021;100(4S):S1-S276. https:\/\/doi.org\/10.1016\/j.kint.2021.05.021.","DOI":"10.1016\/j.kint.2021.05.021"},{"issue":"3","key":"1150_CR52","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1681\/ASN.2021060771","volume":"33","author":"D Nezam","year":"2022","unstructured":"Nezam D, Porcher R, Grolleau F, et al. Kidney histopathology can predict kidney function in ANCA-associated vasculitides with acute kidney injury treated with plasma exchanges. J Am Soc Nephrol. 2022;33(3):628\u201337. https:\/\/doi.org\/10.1681\/ASN.2021060771.","journal-title":"J Am Soc Nephrol"},{"issue":"3","key":"1150_CR53","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1136\/annrheumdis-2018-214245","volume":"78","author":"RB Jones","year":"2019","unstructured":"Jones RB, Hiemstra TF, Ballarin J, et al. Mycophenolate mofetil versus cyclophosphamide for remission induction in ANCA-associated vasculitis: a randomised, non-inferiority trial. Ann Rheum Dis. 2019;78(3):399\u2013405. https:\/\/doi.org\/10.1136\/annrheumdis-2018-214245.","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"1150_CR54","doi-asserted-by":"publisher","first-page":"2190","DOI":"10.1093\/ndt\/gfab357","volume":"37","author":"A Berti","year":"2022","unstructured":"Berti A, Alsawas M, Jawaid T, et al. Induction and maintenance of remission with mycophenolate mofetil in ANCA-associated vasculitis: a systematic review and meta-analysis. Nephrol Dial Transplant. 2022;37(11):2190\u2013200. https:\/\/doi.org\/10.1093\/ndt\/gfab357.","journal-title":"Nephrol Dial Transplant"},{"issue":"19","key":"1150_CR55","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.1056\/NEJMoa1404231","volume":"371","author":"L Guillevin","year":"2014","unstructured":"Guillevin L, Pagnoux C, Karras A, et al. Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis. N Engl J Med. 2014;371(19):1771\u201380. https:\/\/doi.org\/10.1056\/NEJMoa1404231.","journal-title":"N Engl J Med"},{"issue":"8","key":"1150_CR56","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1136\/annrheumdis-2017-212768","volume":"77","author":"B Terrier","year":"2018","unstructured":"Terrier B, Pagnoux C, Perrodeau \u00c9, et al. Long-term efficacy of remission-maintenance regimens for ANCA-associated vasculitides. Ann Rheum Dis. 2018;77(8):1150\u20136. https:\/\/doi.org\/10.1136\/annrheumdis-2017-212768.","journal-title":"Ann Rheum Dis"},{"key":"1150_CR57","doi-asserted-by":"publisher","unstructured":"Charles P, Terrier B, Perrodeau \u00c9, et al. Comparison of individually tailored versus fixed-schedule rituximab regimen to maintain ANCA-associated vasculitis remission: results of a multicentre, randomised controlled, phase III trial (MAINRITSAN2) [published correction appears in Ann Rheum Dis. 2019 Sep;78(9):e101]. Ann Rheum Dis. 2018;77(8):1143\u20131149. https:\/\/doi.org\/10.1136\/annrheumdis-2017-212878.","DOI":"10.1136\/annrheumdis-2017-212878"},{"issue":"7","key":"1150_CR58","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1136\/ard-2022-223559","volume":"82","author":"RM Smith","year":"2023","unstructured":"Smith RM, Jones RB, Specks U, et al. Rituximab versus azathioprine for maintenance of remission for patients with ANCA-associated vasculitis and relapsing disease: an international randomised controlled trial. Ann Rheum Dis. 2023;82(7):937\u201344. https:\/\/doi.org\/10.1136\/ard-2022-223559.","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"1150_CR59","doi-asserted-by":"publisher","first-page":"179","DOI":"10.7326\/M19-3827","volume":"173","author":"P Charles","year":"2020","unstructured":"Charles P, Perrodeau \u00c9, Samson M, et al. Long-term rituximab use to maintain remission of antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial. Ann Intern Med. 2020;173(3):179\u201387. https:\/\/doi.org\/10.7326\/M19-3827.","journal-title":"Ann Intern Med"},{"key":"1150_CR60","doi-asserted-by":"publisher","unstructured":"Delestre F, Charles P, Karras A, et al. Rituximab as maintenance therapy for ANCA-associated vasculitides: pooled analysis and long-term outcome of 277 patients included in the MAINRITSAN trials. Ann Rheum Dis. 2024;83(2):233\u2013241. Published 2024 Jan 11. https:\/\/doi.org\/10.1136\/ard-2023-224623.","DOI":"10.1136\/ard-2023-224623"},{"issue":"10","key":"1150_CR61","doi-asserted-by":"publisher","first-page":"1662","DOI":"10.1136\/annrheumdis-2017-211123","volume":"76","author":"A Karras","year":"2017","unstructured":"Karras A, Pagnoux C, Haubitz M, et al. Randomised controlled trial of prolonged treatment in the remission phase of ANCA-associated vasculitis. Ann Rheum Dis. 2017;76(10):1662\u20138. https:\/\/doi.org\/10.1136\/annrheumdis-2017-211123.","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"1150_CR62","doi-asserted-by":"publisher","first-page":"2949","DOI":"10.1007\/s10067-022-06240-w","volume":"41","author":"IC Van Gool","year":"2022","unstructured":"Van Gool IC, Kers J, Bakker JA, Rotmans JI, Teng YKO, Bauer MP. Antineutrophil cytoplasmic antibodies in infective endocarditis: a case report and systematic review of the literature. Clin Rheumatol. 2022;41(10):2949\u201360. https:\/\/doi.org\/10.1007\/s10067-022-06240-w.","journal-title":"Clin Rheumatol"},{"key":"1150_CR63","doi-asserted-by":"publisher","unstructured":"Cervi A, Kelly D, Alexopoulou I, Khalidi N. ANCA-associated pauci-immune glomerulonephritis in a patient with bacterial endocarditis: a challenging clinical dilemma. Clin Nephrol Case Stud. 2017;5:32\u201337. Published 2017 Apr 26. https:\/\/doi.org\/10.5414\/CNCS109076.","DOI":"10.5414\/CNCS109076"},{"key":"1150_CR64","doi-asserted-by":"publisher","unstructured":"Sexton DJ, Spelman D. Current best practices and guidelines. Assessment and management of complications in infective endocarditis. Cardiol Clin. 2003;21(2):273-viii. https:\/\/doi.org\/10.1016\/s0733-8651(03)00031-6.","DOI":"10.1016\/s0733-8651(03)00031-6"},{"issue":"6","key":"1150_CR65","doi-asserted-by":"publisher","first-page":"447","DOI":"10.5414\/cnp66447","volume":"66","author":"N Kishimoto","year":"2006","unstructured":"Kishimoto N, Mori Y, Yamahara H, et al. Cytoplasmic antineutrophil cytoplasmic antibody positive pauci-immune glomerulonephritis associated with infectious endocarditis. Clin Nephrol. 2006;66(6):447\u201354. https:\/\/doi.org\/10.5414\/cnp66447.","journal-title":"Clin Nephrol"},{"issue":"2","key":"1150_CR66","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1093\/ckj\/sft165","volume":"7","author":"SH Shah","year":"2014","unstructured":"Shah SH, Grahame-Clarke C, Ross CN. Touch not the cat bot a glove*: ANCA-positive pauci-immune necrotizing glomerulonephritis secondary to Bartonella henselae. Clin Kidney J. 2014;7(2):179\u201381. https:\/\/doi.org\/10.1093\/ckj\/sft165.","journal-title":"Clin Kidney J"},{"issue":"5","key":"1150_CR67","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1097\/IPC.0000000000000384","volume":"24","author":"JE Raybould","year":"2016","unstructured":"Raybould JE, Raybould AL, Morales MK, et al. Bartonella endocarditis and pauci-immune glomerulonephritis: a case report and review of the literature. Infect Dis Clin Pract (Baltim Md). 2016;24(5):254\u201360. https:\/\/doi.org\/10.1097\/IPC.0000000000000384.","journal-title":"Infect Dis Clin Pract (Baltim Md)"},{"issue":"12","key":"1150_CR68","doi-asserted-by":"publisher","first-page":"4081","DOI":"10.1128\/JCM.01095-07","volume":"45","author":"HR Vikram","year":"2007","unstructured":"Vikram HR, Bacani AK, DeValeria PA, Cunningham SA, Cockerill FR 3rd. Bivalvular Bartonella henselae prosthetic valve endocarditis. J Clin Microbiol. 2007;45(12):4081\u20134. https:\/\/doi.org\/10.1128\/JCM.01095-07.","journal-title":"J Clin Microbiol"},{"issue":"3","key":"1150_CR69","doi-asserted-by":"publisher","first-page":"207","DOI":"10.3109\/03009742.2012.739638","volume":"42","author":"JW Gregersen","year":"2013","unstructured":"Gregersen JW, Chaudhry A, Jayne DR. Rituximab for ANCA-associated vasculitis in the setting of severe infection. Scand J Rheumatol. 2013;42(3):207\u201310. https:\/\/doi.org\/10.3109\/03009742.2012.739638.","journal-title":"Scand J Rheumatol"},{"key":"1150_CR70","doi-asserted-by":"publisher","unstructured":"Chandok T, Nasr R, Uday KA. A case of antineutrophil cytoplasmic antibody vasculitis-associated acute kidney injury in a patient with asymptomatic COVID-19 infection. Cureus. 2023;15(2):e35006. Published 2023 Feb 15. https:\/\/doi.org\/10.7759\/cureus.35006.","DOI":"10.7759\/cureus.35006"},{"key":"1150_CR71","doi-asserted-by":"publisher","unstructured":"Kataria S, Rogers S, Sadia H, et al. Antineutrophil cytoplasmic antibody (ANCA)-associated renal vasculitis after COVID-19 infection: a case report. Cureus. 2022;14(6):e26111. Published 2022 Jun 20. https:\/\/doi.org\/10.7759\/cureus.26111.","DOI":"10.7759\/cureus.26111"},{"issue":"7","key":"1150_CR72","doi-asserted-by":"publisher","first-page":"e28754","DOI":"10.1097\/MD.0000000000028754","volume":"101","author":"MJ Alawad","year":"2022","unstructured":"Alawad MJ, Subahi EA, Al-Ani HA, Taha NM, Kamal I. A case of crescentic glomerulonephritis in a patient with COVID-19 infection: a case report and literature review. Medicine (Baltimore). 2022;101(7):e28754. https:\/\/doi.org\/10.1097\/MD.0000000000028754.","journal-title":"Medicine (Baltimore)"},{"issue":"11","key":"1150_CR73","doi-asserted-by":"publisher","first-page":"2079","DOI":"10.1016\/j.ekir.2020.08.012","volume":"5","author":"NN Uppal","year":"2020","unstructured":"Uppal NN, Kello N, Shah HH, et al. De novo ANCA-associated vasculitis with glomerulonephritis in COVID-19. Kidney Int Rep. 2020;5(11):2079\u201383. https:\/\/doi.org\/10.1016\/j.ekir.2020.08.012.","journal-title":"Kidney Int Rep"},{"issue":"4","key":"1150_CR74","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1007\/s00467-021-04944-w","volume":"36","author":"M Basiratnia","year":"2021","unstructured":"Basiratnia M, Derakhshan D, Yeganeh BS, Derakhshan A. Acute necrotizing glomerulonephritis associated with COVID-19 infection: report of two pediatric cases. Pediatr Nephrol. 2021;36(4):1019\u201323. https:\/\/doi.org\/10.1007\/s00467-021-04944-w.","journal-title":"Pediatr Nephrol"},{"issue":"2","key":"1150_CR75","doi-asserted-by":"publisher","first-page":"125","DOI":"10.2147\/tcrm.1.2.125.62913","volume":"1","author":"DL McDanel","year":"2005","unstructured":"McDanel DL, Muller BA. The linkage between Churg-Strauss syndrome and leukotriene receptor antagonists: fact or fiction? Ther Clin Risk Manag. 2005;1(2):125\u201340. https:\/\/doi.org\/10.2147\/tcrm.1.2.125.62913.","journal-title":"Ther Clin Risk Manag"},{"issue":"5","key":"1150_CR76","doi-asserted-by":"publisher","first-page":"R1072","DOI":"10.1186\/ar1789","volume":"7","author":"B Bonaci-Nikolic","year":"2005","unstructured":"Bonaci-Nikolic B, Nikolic MM, Andrejevic S, Zoric S, Bukilica M. Antineutrophil cytoplasmic antibody (ANCA)-associated autoimmune diseases induced by antithyroid drugs: comparison with idiopathic ANCA vasculitides. Arthritis Res Ther. 2005;7(5):R1072\u201381. https:\/\/doi.org\/10.1186\/ar1789.","journal-title":"Arthritis Res Ther"},{"key":"1150_CR77","doi-asserted-by":"publisher","unstructured":"Chen M, Gao Y, Guo XH, Zhao MH. Propylthiouracil-induced antineutrophil cytoplasmic antibody-associated vasculitis. Nat Rev Nephrol. 2012;8(8):476\u2013483. Published 2012 Jun 5. https:\/\/doi.org\/10.1038\/nrneph.2012.108.","DOI":"10.1038\/nrneph.2012.108"},{"issue":"1","key":"1150_CR78","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1684\/ejd.2016.2881","volume":"27","author":"CM Magro","year":"2017","unstructured":"Magro CM, Momtahen S, Harp J. The distinctive histopathology of hydralazine-associated ANCA positive vasculitis: in vivo demonstration of NETosis. Eur J Dermatol. 2017;27(1):91\u20132. https:\/\/doi.org\/10.1684\/ejd.2016.2881.","journal-title":"Eur J Dermatol"},{"issue":"1","key":"1150_CR79","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1002\/art.41902","volume":"74","author":"S Deshayes","year":"2022","unstructured":"Deshayes S, Dolladille C, Dumont A, et al. A worldwide pharmacoepidemiologic update on drug-induced antineutrophil cytoplasmic antibody-associated vasculitis in the era of targeted therapies. Arthritis Rheumatol. 2022;74(1):134\u20139. https:\/\/doi.org\/10.1002\/art.41902.","journal-title":"Arthritis Rheumatol"},{"key":"1150_CR80","doi-asserted-by":"publisher","unstructured":"Jin Q, Kant S, Alhariri J, Geetha D. Levamisole adulterated cocaine associated ANCA vasculitis: review of literature and update on pathogenesis. J Community Hosp Intern Med Perspect. 2018;8(6):339\u2013344. Published 2018 Dec 11. https:\/\/doi.org\/10.1080\/20009666.2018.1536242.","DOI":"10.1080\/20009666.2018.1536242"},{"issue":"2","key":"1150_CR81","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1093\/rheumatology\/keaa215","volume":"60","author":"S Monti","year":"2021","unstructured":"Monti S, Craven A, Klersy C, et al. Association between age at disease onset of anti-neutrophil cytoplasmic antibody-associated vasculitis and clinical presentation and short-term outcomes. Rheumatology (Oxford). 2021;60(2):617\u201328. https:\/\/doi.org\/10.1093\/rheumatology\/keaa215.","journal-title":"Rheumatology (Oxford)"},{"issue":"7","key":"1150_CR82","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.2215\/CJN.00480115","volume":"10","author":"M Weiner","year":"2015","unstructured":"Weiner M, Goh SM, Mohammad AJ, et al. Outcome and treatment of elderly patients with ANCA-associated vasculitis. Clin J Am Soc Nephrol. 2015;10(7):1128\u201335. https:\/\/doi.org\/10.2215\/CJN.00480115.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"7","key":"1150_CR83","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1038\/ki.2010.489","volume":"79","author":"AS Bomback","year":"2011","unstructured":"Bomback AS, Appel GB, Radhakrishnan J, et al. ANCA-associated glomerulonephritis in the very elderly. Kidney Int. 2011;79(7):757\u201364. https:\/\/doi.org\/10.1038\/ki.2010.489.","journal-title":"Kidney Int"},{"issue":"Suppl 5","key":"1150_CR84","doi-asserted-by":"publisher","first-page":"v5","DOI":"10.1093\/ndt\/gfg1033","volume":"18","author":"S Kaplan-Pavlovcic","year":"2003","unstructured":"Kaplan-Pavlovcic S, Cerk K, Kveder R, Lindic J, Vizjak A. Clinical prognostic factors of renal outcome in anti-neutrophil cytoplasmic autoantibody (ANCA)-associated glomerulonephritis in elderly patients. Nephrol Dial Transplant. 2003;18(Suppl 5):v5\u20137. https:\/\/doi.org\/10.1093\/ndt\/gfg1033.","journal-title":"Nephrol Dial Transplant"},{"issue":"9","key":"1150_CR85","doi-asserted-by":"publisher","first-page":"2427","DOI":"10.1007\/s10067-023-06644-2","volume":"42","author":"F Aqeel","year":"2023","unstructured":"Aqeel F, Xu L, Salas A, Wen Y, Eid SM, Geetha D. Outcomes of remission induction therapy for ANCA-associated vasculitis in the elderly. Clin Rheumatol. 2023;42(9):2427\u201335. https:\/\/doi.org\/10.1007\/s10067-023-06644-2.","journal-title":"Clin Rheumatol"},{"issue":"5","key":"1150_CR86","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1093\/rheumatology\/kez388","volume":"59","author":"D McGovern","year":"2020","unstructured":"McGovern D, Williams SP, Parsons K, et al. Long-term outcomes in elderly patients with ANCA-associated vasculitis. Rheumatology (Oxford). 2020;59(5):1076\u201383. https:\/\/doi.org\/10.1093\/rheumatology\/kez388.","journal-title":"Rheumatology (Oxford)"},{"key":"1150_CR87","doi-asserted-by":"publisher","unstructured":"Manno RL, Seo P, Geetha D. Older patients with ANCA-associated vasculitis and dialysis dependent renal failure: a retrospective study. BMC Nephrol. 2015;16:88. Published 2015 Jun 25. https:\/\/doi.org\/10.1186\/s12882-015-0082-9.","DOI":"10.1186\/s12882-015-0082-9"},{"key":"1150_CR88","doi-asserted-by":"publisher","unstructured":"Tieu J, Smith RM, Gopaluni S, et al. Rituximab associated hypogammaglobulinemia in autoimmune disease. Front Immunol. 2021;12:671503. Published 2021 May 12. https:\/\/doi.org\/10.3389\/fimmu.2021.671503.","DOI":"10.3389\/fimmu.2021.671503"},{"issue":"2","key":"1150_CR89","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1016\/j.kint.2022.04.035","volume":"102","author":"BM Churilla","year":"2022","unstructured":"Churilla BM, Aqeel F, Azar A, et al. Do the benefits of subcutaneous immunoglobulin therapy for secondary hypogammaglobulinemia in ANCA vasculitis extend beyond infection prevention? Kidney Int. 2022;102(2):444\u20135. https:\/\/doi.org\/10.1016\/j.kint.2022.04.035.","journal-title":"Kidney Int"}],"container-title":["Current Rheumatology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11926-024-01150-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11926-024-01150-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11926-024-01150-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,4]],"date-time":"2024-07-04T09:31:02Z","timestamp":1720085462000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11926-024-01150-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,6]]},"references-count":89,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["1150"],"URL":"https:\/\/doi.org\/10.1007\/s11926-024-01150-z","relation":{},"ISSN":["1523-3774","1534-6307"],"issn-type":[{"value":"1523-3774","type":"print"},{"value":"1534-6307","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,6]]},"assertion":[{"value":"26 April 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Duvuru Geetha has served as consultant for Amgen, ChemoCentryx, GSK, Otsuka, Aurinia Inc and Calliditas. Faten Aqeel: none.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights"}}]}}